http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4#Head
http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4#assertion
http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4#provenance
http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4#pubinfo
http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4#assertion
http://purl.obolibrary.org/obo/DOID_7148
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_7148
http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB08895
http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4#association
http://www.w3.org/2000/01/rdf-schema#label
xeljanz xeljanz xr is a janus kinase jak inhibitor rheumatoid arthritis limitations of use 1 psoriatic arthritis limitations of use 1 ulcerative colitis limitations of use 1 rheumatoid arthritis xeljanz xeljanz xr is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate it may be used as monotherapy or in combination with methotrexate or other nonbiologic disease modifying antirheumatic drugs dmards limitations of use use of xeljanz xeljanz xr in combination with biologic dmards or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended psoriatic arthritis xeljanz xeljanz xr is indicated for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other disease modifying antirheumatic drugs dmards limitations of use use of xeljanz xeljanz xr in combination with biologic dmards or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended ulcerative colitis xeljanz is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis uc limitations of use use of xeljanz in combination with biological therapies for uc or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended
http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB08895
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4#provenance
http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4#pubinfo
http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4#sig
http://purl.org/nanopub/x/hasSignature
JMe/DXRQeGZNv9fu1EXp2k0u5UBrXUb4STGw8AkfBSl7u8VeiPFv+g18jeriV0ELaFb6rfaTCoqgPk/QIaxt466NVpmuG1j4U+EuXf5X0JunaHZrMHgWdR2256HzyAtQBtDMayuapCht9EzeEmwDwatEv6SnfoZeOzc0sGVXgGM=
http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4
http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4
http://purl.org/dc/terms/created
2021-07-03T14:28:19.986+02:00
http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs